Coverage includes:
- Stem cell models for drug screening
- Stem cells for toxicity assessment
- Stem cells as novel drug targets
- Cancer stem cells
- Role of stem cells in big pharma
- High-content screening of stem cells
Distinguished Faculty:
Paul. D. Andrews, Ph.D., Senior Scientist, Stem Cell Programme, Drug Discovery Unit, College of Life Sciences, University of Dundee
Joshua E. Babiarz, Ph.D., Principal Scientist, Non-Clinical Safety, F. Hoffmann-La Roche, Ltd.
Peter Chu, Ph.D., Scientist, Discovery Cancer Therapeutics Group, Biogen Idec, Inc.
Brent Cochran, Ph.D., Principal Investigator, Department of Physiology, Tufts University School of Medicine
Davide Danovi, M.D., Ph.D., Neural Stem Cells Group, UCL Cancer Institute, University College London
Hakim Djaballah, Ph.D., Director, HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center
Jennie Mather, Ph.D., Senior Vice President, Stem Cell Research, MacroGenics
William Matsui, M.D., Associate Professor, Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Yaping Liu, Ph.D., Senior Research Biologist, Automated Biotechnology, Merck Research Labs
Peter Sartipy, Ph.D., Senior Principal Scientist, Project Manager, Cellartis AB
Sanjeev Satyal, Ph.D., Director, Cancer Biology, OncoMed
Jan M. Van Tornout, M.D., M.Sc., Group Director & Lead EDT #2, Discovery Medicine Oncology/Immunology, Bristol-Myers Squibb Co.
Stephen Wong, Ph.D., Chair, Professor and Director, Center for Bioengineering and Informatics, The Methodist Hospital Research Institute, Weill Cornell Medical College
Xianmin Zeng, Ph.D., Associate Professor and Director, Laboratory for Stem Cells and Aging, Buck Institute
For more information, please contact:Julia Boguslavsky, Executive Director, Conferences
E-mail: juliab@healthtech.com
For sponsorship information, please contact:Carol Dinerstein, Business Development
Phone: 781-972-5471; E-mail: dinerstein@healthtech.com